Medical

myelotoxic

myelotoxic

 [mi´ĕ-lo-tok″sik]
1. destructive to bone marrow.
3. arising from diseased bone marrow.
Miller-Keane Encyclopedia and Dictionary of Medicine, Nursing, and Allied Health, Seventh Edition. © 2003 by Saunders, an imprint of Elsevier, Inc. All rights reserved.

my·e·lo·tox·ic

(mī'ĕ-lō-tok'sik),
1. Inhibitory, depressant, or destructive to one or more of the components of bone marrow.
2. Pertaining to, derived from, or manifesting the features of diseased bone marrow.
Farlex Partner Medical Dictionary © Farlex 2012

my·e·lo·tox·ic

(mī'ĕ-lō-tok'sik)
1. Inhibitory, depressant, or destructive to one or more of the components of bone marrow.
2. Pertaining to, derived from, or manifesting the features of diseased bone marrow.
Medical Dictionary for the Health Professions and Nursing © Farlex 2012
Mentioned in
References in periodicals archive
(50,52) Previous use of myelotoxic chemotherapy and radiotherapy to red marrow are strong predictors of hematotoxicity following PRRT.
Cases of chemotherapy (myelotoxic) induced pancytopenia were excluded.
A known myelotoxic agent, benzene affects erythrocytes, leukocytes and platelets, respectively causing anemia, polychromasia, basophilic stippling and peripheral erythroblasts, lymphopenia and thrombocytopenia (28).
Numerous studies conducted have shown that the frequency of each condition differs considerably depending on the differences in methodology, stringency of diagnostic criteria, period of observation, geographic area, age pattern, nutritional status, prevalence of infectious diseases, genetic differences, and varying exposure to myelotoxic agents among other factors.
The randomised, multi-centre, double-blind, placebo-controlled phase III study investigated the safety and efficacy of a once-per-cycle dose of F-627 in women with stage II-IV breast cancer who are receiving myelotoxic TA chemotherapy treatment (Taxotere (docetaxel + Adriamycin (doxorubicin)), with participants randomised 2:1.
Among these side effects, the most serious one that raises the most controversy is the myelotoxic effect.
Tacrolimus metabolite M-III may have nephrotoxic and myelotoxic effects and increase the incidence of infections in kidney transplant recipients.
The etiology of thrombocytopenia in liver disease include portal hypertension (through hypersplenism), antibody-mediated platelet destruction (mainly in viral hepatitis), decreased thrombopoietin production by diseased liver and myelotoxic effects of alcohol and hepatitis virus6.
In addition, the shortened platelet mean lifetime and myelotoxic effects of alcohol or hepatitis viruses also reduced the platelet count.
Copyright © 2003-2025 Farlex, Inc Disclaimer
All content on this website, including dictionary, thesaurus, literature, geography, and other reference data is for informational purposes only. This information should not be considered complete, up to date, and is not intended to be used in place of a visit, consultation, or advice of a legal, medical, or any other professional.